Optimal time-points for minimal residual disease monitoring change on the basis of the method used in patients with acute myeloid leukemia who underwent allogeneic stem cell transplantation: A comparison between multiparameter flow cytometry and Wilms' tumor 1 expression

Leukemia Research

Volumn 39, Issue 2, 2015, Pages 138-143

  Rossi, Giovanni ^a   Carella, Angelo Michele ^a   Minervini, Maria Marta ^a   di Nardo, Francesco ^b   Waure, Chiara de ^b   Greco, Michele Mario ^a   Merla, Emanuela ^a   Cillis, Giovanni Pio de ^a   Di Renzo, Nicola ^c   Melpignano, Angela ^d   Capalbo, Silvana ^e   Palumbo, Gaetano ^e   Pisapia, Giovanni ^f   Cascavilla, Nicola ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c VITO FAZZI HOSPITAL   (Italy)

^d PERRINO HOSPITAL   (Italy)

^e Riuniti Hospital   (Italy)

^f 'SG Moscati SS Annunziata' Hospital   (Italy)

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Minimal residual disease; Multiparameter flow cytometry; WT1 expression

Indexed keywords

WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PATIENT MONITORING; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; THERAPY EFFECT; ADOLESCENT; ALLOGRAFT; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PATHOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ALLOGRAFTS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; STEM CELL TRANSPLANTATION; WT1 PROTEINS;

EID: 84921436191     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.11.011     Document Type: Article

References (26)

1. Wheatley K., Burnett A.K., Goldstone A.H., Gray R.G., Hann I.M., Harrison C.J., et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRCAML 10 trial. Br J Haematol 1999, 107:69-79.
2. Cornelissen J.J., van Putten W.L., Verdonck L.F., Theobald M., Jacky E., Daenen S.M., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 2007, 109:3658-3666.
3. Wang Y., Liu D.H., Liu K.Y., Xu L.P., Zhang X.H., Han W., et al. Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013, 19:283-290.
4. Schlenk R.F., Benner A., Hartmann F., del Valle F., Weber C., Pralle H., et al. Risk- adapted post-remission therapy in acute myeloid leukemia: results of the German Multicenter AML HD93 treatment trial. Leukemia 2003, 17:1521-1528.
5. Kröger N., Bacher U., Bader P., Böttcher S., Borowitz M.J., Dreger P., et al. NCI First International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. Part I: methods, acute leukemias, and myelodisplastic syndromes. Biol Blood Marrow Transplant 2010, 16:1187-1211.
6. Walter R.B., Buckley S.A., Pagel J.M., Wood B.L., Storer B.E., Sandmaier B.M., et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2014, 122:1813-1821.
7. Walter R.B., Gooley T.A., Wood B.L., Milano F., Fang M., Sorror M.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcomeof myeloablative hemopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011, 29(9):1190-1197.
8. Maurillo L., Buccisano F., Del Principe M.I., Del Poeta G., Spagnoli A., Panetta P., et al. Toward optimization of post-remission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008, 26:4944-4951.
9. Valkova V., Polak J., Markova M., Vítek A., Hájková H., Sálek C., et al. Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. Clin Transplant 2013, 27:21-29.
10. Ogawa H., Tamaki H., Ikegame K., Soma T., Kawakami M., Tsuboi A., et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003, 101:1698-1704.
11. Candoni A., Tiribelli M., Toffoletti E., Cilloni D., Chiarvesio A., Michelutti A., et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009, 82(1):61-68.
12. Zhao X.S., Jin S., Zhu H.H., Xu L.P., Liu D.H., Chen H., et al. Wilms' tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant 2012, 47(4):499-507.
13. Pozzi S., Geroldi S., Tedone E., Luchetti S., Grasso R., Colombo N., et al. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. Br J Haematol 2013, 160:503-509.
14. Kwon M., Martinez-Laperche C., Infante M., Carretero F., Balsalobre P., Serrano D., et al. Evaluation of minimal residual disease by real-time quantitative PCR of Wilm's tumor I expression in patients with acute myelogenous leukemia after allogeneic stem cell transplantation: correlation with flow cytometry and chimerism. Biol Blood Marrow Transplant 2012, 1:1-8.
15. Miyazaki T., Fujita H., Fujimaki K., Hosoyama T., Watanabe R., Tachibana T., et al. Clinical significance of minimal residual disease detected by multidimensional flow cytometry: serial monitoring after allogeneic stem cell transplantation for acute leukemia. Leuk Res 2012, 36:998-1003.
16. Rossi G., Carella A.M., Minervini M.M., Savino L., Fontana A., Pellegrini F., et al. Minimal residual disease after allogeneic stem cell transplantation: a comparison among multiparametric flow cytometry Wilms tumor 1 expression and chimerism status (complete chimerism versus low level mixed chimerism) in acute leukemia. Leuk Lymphoma 2013, 54:2660-2666.
17. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 Worlds Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important change. Blood 2009, 114:937-951.
18. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estery E.H., et al. International Working Group for diagnosis. Revised recommendations of response criteria. Treatments outcomes and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003, 21:4642-4649.
19. Grimwade D., Hills R.K., Moorman A.V., Walker H., Chatters S., Goldstone A.H., et al. National cancer research institute adult leukaemia working group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United kingdom Medical research Council trials. Blood 2010, 116:354-365.
20. Cilloni D., Renneville A., Hermitte F., Hills R.K., Daly S., Jovanovic J.V., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet Study. J Clin Oncol 2009, 27:5195-5201.
21. Van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukemia. Leukemia 1999, 13:1901-1928.
22. Diez-Campelo M., Perez-Simon J.A., Perez J., Alcoceba M., Richtmon J., Vidriales B., et al. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 2009, 84:149-152.
23. Rossi G., Minervini M.M., Melillo L., di Nardo F., de Waure C., Scalzulli P.R., et al. Predictive role of minimal residual disease and log clearance in acute myeloid leukemia: a comparison between multiparameter flow cytometry and Wilm's tumor 1 levels. Ann Hematol 2014, 10.1007/s00277-014-2029-9.
24. Rossi G., Nomdedeu J.F., Fontana A., Minervini M.M., García-Dabrio M.C., Cascavilla N. CD117-CD15 in acute myeloid leukemia: no role as LAIP in the study of minimal residual disease. Eur J Haematol 2013, 90(2):171-174.
25. van de Loosdrecht A.A., Alhan C., Béné M.C., Della Porta M.G., Dräger A.M., Feuillard J., et al. Standardization of flow cytometry in myelodisplastic syndromes. Report from the first European LeukemiaNet working conference on flow cytometry in myelodisplastic syndromes. Haematologica 2009, 94(8):1124-1134.
26. Alonso-Dominguez J.M., Tenorio M., Velasco D., Abalo L., Lozano S., Villarrubia J., et al. Correlation of WT1 expression with the burden of total and residual leukemic blasts in bone marrow samples of acute myeloid leukemia patients. Cancer Genet 2012, 205:190-191.